©2019 by ImmunoDiagnostics Limited.

Cystatin C protein

SKU: 41240-S10

Type:

Recombinant

Cat. No.:

41240-S10

Tag:

6xHis-tag

Size:

1 mg

Source:

E.Coli

Purity:

>95%

Other names:

Cystatin 3, CST3

Species:

Human

  • INTRODUCTION

    Human cystatin C (or cystatin 3), which is composed of 120 amino acid residues, belongs to the cystatins superfamilly that inactivates lysosomal cysteine proteinases. As a strongly cationic and low-molecular weight (13.4 kDa) protein, it is almost freely filtered across the glomerular membrane, and is mainly used as a biomarker of kidney function. A growing body of evidence suggests that cystatin C is a more reliable biomarker of glomerular filtration rate than creatinine [1-3].
    In addition to kidney disease, altered serum levels of cystatin C are associated with several types of cardiovascular disease, including myocardial infarction, stroke, heart failure, peripheral arterial disease and metabolic syndrome [4-7]. It also seems to play a role in brain disorders involving amyloid, such as Alzheimer's disease [8, 9]. Furthermore, Cystatin C has also been investigated as a prognostic marker in several forms of cancer [10-12].

    Expressed in E.Coli. N-terminal 6xHis-tag and TEV cleavage site

    Recombinant antigen for research use or manufacturing only.

  • DATA SHEET

  • FORMULATION

    Solution in PBS.

  • APPLICATION/ USAGE

    Standard ELISA test, Western blotting

  • QUALITY CONTROL TEST

    BCA to determine quantity of the protein.

    SDS-PAGE to determine purity of the protein.

  • STORAGE

    Store at –20°C. For long-term storage, aliquot and freeze at -70°C. Avoid repeated freeze/defrost cycles.

  • REFERENCE

    [1] Stevens LA, Coresh J, Schmid CH, et al. (2008) Am J Kidney Dis. 51:395–406.
    [2] Dharnidharka VR, Kwon C, Stevens G. (2002) Am. J. Kidney Dis. 40 (2): 221–6.
    [3] Hermida J, Tutor JC. (2006) Ther Drug Monit. 28 (3): 326–31.
    [4] Zethelius B, Berglund L, Sundström J, et al. (2008) N. Engl. J. Med. 358 (20): 2107–16.
    [5] Ix JH, Shlipak MG, Chertow GM, Whooley MA. (2007) Circulation 115 (2): 173–9.
    [6] Deo R, Fyr CL, Fried LF, et al. (January 2008) Am. Heart J. 155 (1): 62–8. 
    [7] Servais A, Giral P, Bernard M, et al. (2008) Am. J. Med. 121 (5): 426–32.
    [8]Mi W, Pawlik M, Sastre M, et al. (2007) Nat. Genet. 39 (12): 1440–2.
    [9] Kaeser SA, Herzig MC, Coomaraswamy J, et al. (2007) Nat. Genet. 39 (12): 1437–9.
    [10] Zurdel J, Finckh U, Menzer G, et al. (2002) Br J Ophthalmol 86 (2): 214–9.
    [11] Strojan P, Oblak I, Svetic B, et al. (2004) Br. J. Cancer 90 (10): 1961–8. 
    [12] Kos J, Krasovec M, Cimerman N, et al. (2000) Clin. Cancer Res. 6 (2): 505–11.

$400.00Price